-
MedImmune accepts $15.6 billion buy-out offer
AstraZeneca outbids Merck and others to get its hands on the FluMist vaccine
-
-
TB victim receives TV
Facing a life of civil commitment, Russian-born Arizonan earns his creature comforts
-
-
General Dynamics Canada wins Canadian bio-sensor contract
After six years of succesful naval deployments, government will buy CAN$30 million worth of GDC’s VP Bio Sentry systems
-
-
Biotech industry set to break flu vaccine production record
Officials say industry will produce 132 million doses, with both Sanofi and MedImmune ramping up production capacity
-
-
FDA approves first bird flu vaccine
Government has been stockpiling Sanofi Pasteur’s vaccine for some time, but now it can be distributed without signed consent; concerns remain about efficacy
-
-
Digital angel buys Chemring's McMurdo
$7.5 million deal expected to pay dividends in 2009 when COSPAS-SARSAT equipment is replaced
-
-
NIH awards $23 million for six new influzena research centers
Federal government gets serious by expanding the Centers of Excellence for Influenza Research and Surveillance program
-
-
VaxGen tries to regroup
After HHS cancels its $877 million anthrax vaccine, company looks to merge or partner with others
-
-
Protein Sciences tests caterpillar-based flu vaccine
New approach to vaccine development relies on insect cells rather than bird eggs; method offers improved speed and safety
-
-
MedImmune to explore buy-out options
Board of directors reacts to heightened interest from Big Pharma and growing shareholder disatisfication
-
-
New technology turns A and B blood to O
A fresh approach to an old concept, ZymeQuest tests a machine capable of treating eight units in ninety minutes
-
-
DoE tests Isonics's aerosol bio-decontamination system
Company receives $1 million in funding to perfect technology; tests come as Isonics faces delisting from Nasdaq
-
-
Florida may reject federal flu assistance
Leading state legislator says discounted Tamiflu and Relenza are not “one of my priorities”; public health experts call proposol shortsighted and uneconomical
-
-
Researchers overcome antibiotic-resistant bacteria
Newly-discovered peptide works wonders against Staph and VRE; as approach does not directly act on bacteria, researchers say resistance is unlikely
-
-
Smiths Detection wins two major DoD contracts
Chemical detection units earn $19 million for this industry heavyweight; Air Force spends $4.5 million on advanced hazmat identification equipment
-
The long view
A Shining Star in a Contentious Legacy: Could Marty Makary Be the Saving Grace of a Divisive Presidency?
While much of the Trump administration has sparked controversy, the FDA’s consumer-first reforms may be remembered as its brightest legacy. From AI-driven drug reviews to bans on artificial dyes, the FDA’s agenda resonates with the public in ways few Trump-era policies have.